AstraZeneca presents positive data on ceftazidime-avibactam for multi-drug gram-negative infections

11 April 2016

Anglo-Swedish pharma major AstraZeneca (LSE: AZN) has presented positive data on the investigational antibiotic, ceftazidime-avibactam (CAZ-AVI), in treating patients with ceftazidime-resistant Gram-negative infections.

The data, from a pooled analysis of seven clinical trials of patients with either complicated intra-abdominal infections (cIAI) or complicated urinary tract infections (cUTI), showed ceftazidime-avibactam was effective at treating patients with ceftazidime-resistant gram-negative pathogens caused by Enterobacteriaceae and Pseudomonas aeruginosa.

CAZ-AVI was equally effective at treating patients with ceftazidime-resistant or ceftazidime-susceptible gram-negative pathogens, regardless of underlying infection. Response rates were similar to carbapenem comparators. Alongside cIAI and cUTI, CAZ-AVI is also being studied for the treatment of nosocomial pneumonia, including hospital acquired pneumonia and ventilator associated pneumonia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK